Diego López Otero (@birihh) 's Twitter Profile
Diego López Otero

@birihh

Jefe de Servicio de Cardiologia Área Sanitaria de Pontevedra e O Salnés.

ID: 2154528550

calendar_today26-10-2013 16:34:39

95 Tweet

230 Followers

95 Following

DapaTAVI (@dapatavi) 's Twitter Profile Photo

El Hospital Clínico de Santiago de Compostela CARDIOCHUS también está dentro del DapaTAVI. Uno de los centros de referencia de implante de TAVI que seguro que incluirá muchos pacientes. Gracias Diego López Otero y todo el equipo por la colaboración

Elsevier Español (@elsevier_es) 's Twitter Profile Photo

#EntrevistaConnect #Cardiología @pabloavanzas y Diego López Otero presentan la 2ª ed. de 'Manual de tratamiento percutáneo de la estenosis aórtica', obra de referencia de la especialidad 👉 bit.ly/Cardiologia-Es…

#EntrevistaConnect #Cardiología

@pabloavanzas y <a href="/birihh/">Diego López Otero</a> presentan la 2ª ed. de 'Manual de tratamiento percutáneo de la estenosis aórtica', obra de referencia de la especialidad 

👉 bit.ly/Cardiologia-Es…
REC Publications (@revespcardiol) 's Twitter Profile Photo

Validation of a new model of non-invasive functional assessment of coronary lesions by computer tomography fractional flow reserve #reccardioclinics #AheadOfPrint Diego López Otero José R. Juanatey reccardioclinics.org//es-validation…

EHJCVI Editor-in-Chief (@ehjcvieic) 's Twitter Profile Photo

#EHJCVI AMY-TAVI study examined patients with cardiac #amyloidosis (CA) and #aortic stenosis and the relative apical sparing pattern of LV GLS (RELAPS]>1) 🔥 RELAPS > 1 is not only met in CA ➡️ almost 50% of patients without CA will have this sign academic.oup.com/ehjcimaging/ad…

#EHJCVI AMY-TAVI study examined patients with cardiac #amyloidosis (CA) and #aortic stenosis and the relative apical sparing pattern of LV GLS (RELAPS]&gt;1)

🔥 RELAPS &gt; 1 is not only met in CA ➡️ almost 50% of patients without CA will have this sign 

academic.oup.com/ehjcimaging/ad…
NEJM (@nejm) 's Twitter Profile Photo

Most patients undergoing transcatheter aortic-valve implantation have been excluded from trials of sodium–glucose cotransporter 2 inhibitors. Findings from the DapaTAVI trial on the SGLT2 inhibitor dapagliflozin in these patients are summarized in a short video.

Most patients undergoing transcatheter aortic-valve implantation have been excluded from trials of sodium–glucose cotransporter 2 inhibitors. 

Findings from the DapaTAVI trial on the SGLT2 inhibitor dapagliflozin in these patients are summarized in a short video.